RSK2失活突变增强MAPK信号并支持肝细胞癌胆固醇代谢
对HBV相关肝细胞癌(HCC)行外显子组和靶向测序,发现RSK2复发性体细胞突变率为6.3%,为失活突变且与更具侵袭性的肿瘤表型相关。在天然RSK2缺失的Hep3B细胞中恢复RSK2表达可抑制体外增殖、迁移和体内致瘤性。RSK2失活突变减弱SOS1/2依赖的负反馈,激活MAPK信号,使HCC细胞对索拉非尼更敏感,并增强胆固醇生物合成相关基因表达。
要点
- HCC中RSK2复发性体细胞突变率为6.3%,为失活突变并与更具侵袭性表型相关。
- RSK2失活突变减弱SOS1/2依赖负反馈,激活MAPK信号。
- 该MAPK激活使HCC细胞对索拉非尼更敏感,并增强胆固醇生物合成相关基因表达。
核心结论
- RSK2失活突变可能通过激活MAPK信号和胆固醇代谢参与HCC进展。
- RSK2失活突变可能与更具侵袭性的肿瘤表型相关。
研究设计与样本
- 对HBV相关HCC行外显子组测序和靶向DNA测序以检测RSK2复发性突变。
- 在天然RSK2缺失的HCC细胞和RSK2敲除HCC细胞中研究RSK2突变的功能与机制。
- 通过RNA测序、qRT-PCR和质谱研究RSK2突变的下游通路。
主要发现
- 在HCC队列中检测到RSK2复发性体细胞突变,突变率为6.3%。
- 在多种癌症类型中,HCC是携带RSK2突变最常见的癌症。
- 在天然RSK2缺失的HBV阳性Hep3B细胞中恢复RSK2表达可抑制体外增殖和迁移及体内致瘤性。
- RSK2失活突变减弱SOS1/2依赖的负反馈环路,导致MAPK信号激活。
- RSK2突变介导的MAPK上调使HCC细胞对索拉非尼更敏感,并增强胆固醇生物合成相关基因表达。
临床怎么用
- 作者认为RSK2失活突变可能作为激活HCC中MAPK信号和胆固醇代谢的替代途径。
- 作者认为RSK2突变驱动具有已知致癌潜力的信号通路,导致胆固醇生物合成增强并可能使肿瘤对索拉非尼治疗敏感。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Mutational profiling of patient tumors has suggested that hepatocellular carcinoma (HCC) development is mainly driven by loss-of-function mutations in tumor suppressor genes. p90 ribosomal S6 kinase 2 (RSK2) functions as a direct downstream kinase of ERK1/2 and elevated RSK2 expression has been reported to support oncogenic functions in some cancers. We investigated if RSK2 was also dysregulated by inactivating mutations in cancers including HCC. METHODS: We performed exome sequencing and targeted DNA sequencing on HBV-associated HCCs to examine recurrent RSK2 mutations. The functional significance and mechanistic consequences of RSK2 mutations were examined in natural RSK2-null HCC cells, and RSK2-knockout HCC cells. The potential downstream pathways underlying RSK2 mutations were investigated by RNA sequencing, qRT-PCR and mass spectrometry. RESULTS: We detected recurrent somatic RSK2 mutations at a rate of 6.3% in our HCC cohorts and revealed that, among many cancer types, HCC was the cancer most commonly harboring RSK2 mutations. The RSK2 mutations were inactivating and associated with a more aggressive tumor phenotype. We found that, functionally, restoring RSK2 expression in natural RSK2-null HBV-positive Hep3B cells suppressed proliferation and migration in vitro and tumorigenicity in vivo. Mechanistically, RSK2-inactivating mutations attenuated a SOS1/2-dependent negative feedback loop, leading to the activation of MAPK signaling. Of note, this RSK2 mutation-mediated MAPK upregulation rendered HCC cells more sensitive to sorafenib, a first-line multi-kinase inhibitor for advanced HCC. Furthermore, such activation of MAPK signaling enhanced cholesterol biosynthesis-related gene expression in HCC cells. CONCLUSIONS: Our findings reveal the mechanistic and functional significance of RSK2-inactivating mutations in HCC. These inactivating mutations may serve as an alternative route to activate MAPK signaling and cholesterol metabolism in HCC. LAY SUMMARY: In this study, we identified and functionally characterized RSK2-inactivating mutations in human hepatocellular carcinoma and demonstrated their association with aggressive tumor behavior. Mutations in RSK2 drive signaling pathways with known oncogenic potential, leading to enhanced cholesterol biosynthesis and potentially sensitizing tumors to sorafenib treatment.
引用
- Chan LK, Ho DW, Kam CS, et al. RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. J Hepatol. 2020. PMID: 32918955. doi:10.1016/j.jhep.2020.08.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。